AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.

The U.S. government is looking for ways to restrict the pharma sector’s direct-to-consumer advertising to make it more difficult and costly for companies to run advertisements directly targeting ...

A new AI-driven framework, MapDiff, enhances inverse protein folding accuracy, accelerating the design of proteins for ...

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move ...

NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in ...

Virtual. About Innate Pharma. Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunothera ...

Astrazeneca (AZN) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's ...

An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...